遠大醫藥(00512.HK)擬配售不超1.72億股 淨籌10.14億港元
格隆匯8月2日丨遠大醫藥(00512.HK)宣佈,於2020年8月1日,公司與配售代理訂立配售協議,公司擬透過配售代理按配售價每股5.90港元向不少於6名承配人配售最多1.72億股新股份,佔公司現有已發行股本約5.09%,及佔經擴大後股本約4.85%。
配售事項所得款項總額預期約10.15億港元,所得款項淨額則約10.14億港元。公司計劃將所得款項淨額用於研發項目(包括但不限於公司現有及未來的國內及海外藥品研發)、擴充公司的研發團隊及於技術的投資,預期可以進一步增強公司的研發能力及豐富公司的產品管線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.